Navigation Links
NovaRx Appoints Industry Veteran as President and COO

SAN DIEGO, Dec. 4 /PRNewswire/ -- NovaRx Corporation announced today the appointment of Norrie J.W. Russell, Ph.D to the position of President and Chief Operating Officer. Dr. Russell brings to the company more than 25 years experience in drug discovery and a long history of success driving innovation in pharmaceutical discovery and development. He also has experience leading entrepreneurial biotechnology companies developing pioneering new technologies. Prior to NovaRx, Dr. Russell was the President and CEO of Kalos Therapeutics, a biotechnology company focused on the development of cancer therapies. Before Kalos, he served as Chief Scientific Officer at Invitrogen. He has also served as President and CEO of Aviva Biosciences and Lynx Therapeutics.

Prior to moving to the United States, Dr. Russell had a long career at AstraZeneca, where he was Global Head, Biological Science and Technology, with responsibility for the application of genomics, genetics and proteomics to both target discovery and the entire research and development process. Dr. Russell holds a Ph.D in Physiology from Glasgow University, Scotland.

"We are pleased to have Norrie joining the team," said Justin M. Murdock, CEO and Executive Chairman of NovaRx. "His energy, enthusiasm and experience will help drive NovaRx to new levels and accelerate our ability to get innovative new treatments to cancer patients."

Habib Fakhrai, Ph.D, Executive Vice Chairman of NovaRx and the company's founding scientist, will assume the title of Chief Scientific Officer. Dr. Fakhrai said, "Dr. Russell's appointment comes at an important time for the company as we pursue the late-stage development of our first product Lucanix(R). We welcome the experience he brings."

"I am delighted to be joining NovaRx, it is an exciting company," said Dr. Russell. "Lucanix(R) is a very promising product, which we believe will prove to be a safe and effective treatment for lung cancer patients. My clear priority is to ensure the Phase III study is executed flawlessly. In addition, I will be searching to find the best commercialization partner for Lucanix(R) while growing our tremendous pipeline of new product opportunities."

About NovaRx

Founded in 1997, NovaRx Corporation is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel cell-based therapeutic vaccines for the treatment of cancer. The company's 24,000 square foot headquarters in San Diego, CA, house corporate offices and manufacturing operations. The proprietary core technology upon which Lucanix(R) is based has been exclusively licensed to NovaRx on a worldwide basis. Lucanix(R) is a registered trademark of NovaRx Corporation.

NovaRx's lead product candidate, Lucanix(R), a whole cell-based therapeutic vaccine comprised of four allogeneic cell lines, has completed a Phase II clinical trial for the treatment of progressive non-small cell lung cancer.

Lucanix(R), which was utilized in that Phase II trial to treat advanced stage NSCLC patients (stages IIIB and IV) who had received zero to five prior chemotherapies, demonstrated a one-year survival of 61% and a two-year survival of 41%, and a median survival of 16 months. These late-stage patients typically demonstrate a less than 30% one-year survival. Typical two year survival for stage IV patients is 5% and for stage IIIB is 10% on average. Currently, 59% of the patients who received Lucanix(R) following one frontline regimen of chemotherapy and entered the trial with stable disease have lived over 41 months. Of the patients enrolled in the trial who are still alive, all have lived more than three years, ten have lived more than four years, and three have lived over five years.

Most importantly, Lucanix(R) demonstrated no significant toxicities. Side effects were generally mild and similar to what one might experience after a flu shot. Given these promising results, NovaRx was granted FDA approval to progress Lucanix(R) development in an international, multicenter Phase III clinical trial, which commenced in August 2008.

Although the Company's current clinical trials are for the treatment of advanced non-small cell lung cancer, the majority of other forms of cancer are expected to be susceptible to NovaRx's vaccine approach. One promising NovaRx pipeline therapy, Glionix(TM) for glioma, or brain cancer, has already been tested in Phase I/II clinical trials.

SOURCE NovaRx Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
2. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
3. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
4. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
5. Curemark Appoints Preeminent Pediatrics Gastroenterologist
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. West Pharmaceutical Services, Inc. Appoints New Director
8. Quark Pharmaceuticals Appoints New Chief Medical Officer
9. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
10. Deer Farm Industry in Michigan Issues Statement on the Negative CWD Test Results at Kent County Deer Farm
11. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... ... exchange technology and teleradiology services, has added Chris Hafey and Claude Hooton to ... at the Radiological Society of North America (RSNA) 2015 Annual Meeting and continues ...
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... Denver, CO (PRWEB) , ... November 27, 2015 , ... ... U.S. cities are not changing the way that they are handling security in light ... increasing police and security presence in an attempt to stop an attack from reaching ...
(Date:11/27/2015)... ... 2015 , ... "When I was traveling, I was very ... "Many people catch diseases simply from sitting on such dirty toilet seats. I ... germs." , He developed the patent-pending QUDRATECS to eliminate the need to sit ...
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
Breaking Medicine News(10 mins):